Evidence map›Paper›PMID 36387137›Full record

ArticleFrontiers in oncology2022

Corrigendum: Cross-resistance among sequential cancer therapeutics: An emerging issue.

Rossella Loria, Patrizia Vici, Francesca Sofia Di Lisa, Silvia Soddu, Marcello Maugeri-Saccà, Giulia Bon

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Rossella LoriaCellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Patrizia ViciUnit of Phase IV Trials, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Francesca Sofia Di LisaUnit of Phase IV Trials, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Silvia SodduCellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Marcello Maugeri-SaccàDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Giulia BonCellular Network and Molecular Therapeutic Target Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fonc.2022.877380.].

Indexed as

cancer therapeutics resistancecross-resistancepersonalized oncologysequential therapeuticstargeted-therapy

Identifiers

PMID36387137
PMCPMC9662166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.